EARLY TOXICITIES AND CLINICAL OUTCOMES OF EXTENDED FIELD RADIATION THERAPY WITH VOLUMETRIC MODULATED ARC THERAPY IN PROSTATE CANCER

PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. HISTO-PATHOLOGICALLY PROVEN CASES OF ADENOCARCINOMA PROSTATE.
•2. PATIENTS FULFILLING EITHER OF THE FOLLOWING CRITERIA:
•A) CLINICALLY PELVIC LYMPH NODE POSITIVE NON-METASTATIC DISEASE.
•B) STAGE M1A (PARA-AORTIC NODES/COMMON ILIAC NODAL INVOLVEMENT).
•C) PATHOLOGICAL NODE POSITIVITY AFTER RADICAL PROSTATECTOMY.
•D) POST OP CASES WITH RADIOLOGICALLY POSITIVE LYMPH NODES, TO BE PLANNED FOR SALVAGE RADIOTHERAPY.
•E) HIGH-RISK DISEASE WITH RISK OF LYMPH NODE INVOLVEMENT >15% BY ROACH FORMULA.
•(2/3 X PROSTATE-SPECIFIC ANTIGEN +(GLEASON SCORE-6) x10).
•3. PATIENTS WITH GOOD PERFORMANCE STATUS ECOG 0-2.
•4. PATIENTS WHO GIVE SIGNED INFORMED CONSENT.

•1. PROSTATE CANCER PATIENTS WITH ANY OF THE FOLLOWING.
•A) BONE OR VISCERAL METASTATIC DISEASE.
•B) POSITIVE NON-REGIONAL LYMPH NODES (CLINICAL/IMAGING/PATHOLOGY) OTHER THAN IN COMMON ILIAC OR PARA-AORTIC REGIONS.
•C) HISTORY OF PRIOR RADIOTHERAPY TO PELVIS AND/OR PARA-AORTIC REGION.
•2. PATIENTS WITH POOR PERFORMANCE STATUS ECOG-3/4.
•3. PATIENTS WITH LIFE EXPECTANCY LESS THAN 2 YEARS.

发起方